GLP1-RA Provider Survey White Paper

Insights from Specialty Physicians on GLP-1RA Medications Off-Label Use

Blue

Ali Chappell, PhD, RD, Co-Founder and CEO of Lilli Health, shares how she transformed her experience with PCOS into a data-driven nutrition and wellness company offering services and app to have “a dietitian in your pocket.”


How a PCOS Diagnosis Fueled One Founder’s Mission to Disrupt Women’s Health

The shortage of anti-obesity medications is sending patients to gray markets while healthcare innovators look for longer-term solutions beyond of GLP-1s.

How Entrepreneurs are Looking Beyond GLP-1s for Obesity Innovations

Two NYC-based startups, GenKardia and Sidereal Therapeutics, have each won a $250,000 XSeed Award to support moving promising preclinical research of novel therapies for kidney and heart disease forward toward commercialization.

$250K XSeed Awards Granted to Minority- and Women-Led Startups Advancing New Drugs 

Sidereal Therapeutics is developing a potential first-in-class biologic to prevent acute kidney injury from progressing to chronic disease by targeting iron overload at its source.

Novel Biologic Aims to Stop Kidney Damage Before it Turns Chronic

Vasocure is advancing targeting therapies to prevent arteriovenous graft (AVG) stenosis for patients on kidney dialysis that may also unlock new treatments for atherosclerosis.

How One Company Targets Dialysis Complications with Novel Therapy

Big drugmakers and direct-to-consumer clinics are expanding obesity care with new GLP-1s, cheaper self-pay options and new therapies that may transform this rapidly evolving market.

Obesity Drug Market Charts New Course for Patients, Investors image

Obesity Drug Market Charts New Course for Patients, Investors

Non-invasive devices unveiled at CES 2025 aim to transform metabolic disease prevention and management.

Breaking the Blood Barrier in Metabolic Care at CES 2025

Expert panel explores patient experiences with GLP-1 and the future of obesity treatments at Biotech Showcase 2025.

Reality Check: Doctors Challenge GLP-1 "Magic Drug" Narrative 

To understand GLP-1s use for weight loss, CURE surveyed current and former patients about their attitudes and experience.

Patients Use GLP-1 Drugs for Weight Loss, Gaining Benefits

thumbnail_GLP1RA_patients_survey_GTY2025837217

Patients' Use GLP-1 Drugs for Weight Loss, Benefit Gains

To understand current prescribing practices for off-label use of GLP-1Rs, CURE surveyed physicians across the specialties of gastroenterology, addiction medicine, cardiology, neurology and orthopedics.

The successful treatment of patients with IBD, such as ulcerative colitis or Crohn's disease, might be transformed by Insilico’s ISM5411.



AI-Designed Therapy for Inflammatory Bowel Disease Advances

Lexeo Therapeutics is developing pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.

Lexeo Therapeutics: Revolutionizing Genetic Medicine for Cardiovascular and Neurodegenerative Diseases 

The U.S. government's ARPA-H launched HEROS to make preventing illness as rewarding as delivery acute care for providers, creating more equitable, health outcomes for all Americans.

thumbnail-arpah-heroes-program-preventive

ARPA-H's HEROES Program Accelerates Preventive Health Innovations

XSeed Award Finalist Daria Lizneva, MD, PhD, is developing a potential first-in-class small molecule for the long-term management of obesity.

thumbnail-daria-lizneva-xseed-war-winner-2024

Spotlight on XSeed Award Finalist: Daria Lizneva, MD, PhD, Mount Sinai

Longevity drugs to head off diseases of aging and extend healthy lifespans are tantalizingly close, yet translating basic science discoveries to drugs still have hurdles to pass. James Peyer, PhD, CEO and Founder of Cambrian Bio talks about pursuing treatments that extend human healthspans.

thumbnail_cambrian_Bios_Drug_Strategy_age-related

Cambrian Bio’s Drug Strategy for Age-Related Diseases

Explore the candid opinions of endocrinologists on GLP-1 drugs like Ozempic and Mounjaro. Uncover their thoughts on efficacy, patient satisfaction and the future landscape of these groundbreaking treatments in our white paper.

White Paper GLP-1

What Doctors Really Think of GLP-1 Medications

Maliha Ahmad, MD, an innovator and leader in preventive care for liver disease, believes that re-thinking diagnostics and interventions could change liver health for millions.

The Passion of a Liver Doctor -- Maliha Ahmad MD

Fighting Liver Disease with Detection, AI and Novel Therapies 

Scientific innovations can come from our most personal experiences. For Ed Damiano, PhD, the co-founder of Beta Bionics, his transformational invention began with his son’s diagnosis of type 1 diabetes and an unwavering determination to find a better way to manage the condition.

AI-Powered Companies Dominate 2025 Digital Health Funding

Cure’s Landmark Report Reveals 87% of Healthcare Leaders Remain Optimistic About Future, Despite Challenges

Your Home in NYC

November 11 -13 , 2025

Cure Presents: The X Factor Healthcare Innovation Summit

Accelerating Advances in Health

Metabolic Diseases

Insights

Recommended Topics

Join our community